RecruitingNCT00131014
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies
Sponsor
Dana-Farber Cancer Institute
Enrollment
1,500 participants
Start Date
Aug 9, 2004
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child) with a lymphoproliferative disorder; or families in which the individual has a lymphoproliferative disorder, and an unusual clustering of frequent or premature solid tumors is also observed.
- Family members of the individual, either affected or unaffected with lymphoma, who are contacted by the individual and agree to participate in the study.
- Deceased family members may be included in the study. Public records such as death certificates may be used to confirm the history. Consent for medical records or tissue blocks will be obtained from the deceased family member's next of kin. The hierarchy of relatives defined as next of kin is spouse, offspring, parents and siblings. Archived tissue samples may be used for genetic research.
- Age \> 18 years
Exclusion Criteria1
- Subjects without a family history of lymphoma
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT00131014
Related Trials
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
NCT0307569638 locations
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
NCT015558923 locations
Feasibility of a Multi-omics Platform for Hematological Malignancies
NCT074454381 location
Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
NCT074459841 location
Virtual Rehabilitation for Cancer Survivors
NCT058987891 location